Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
Abstract Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of SGLT2i on renal function and outcome remains unin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-07-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-021-02163-7 |
| _version_ | 1819140000375111680 |
|---|---|
| author | Masaki Nakagaito Teruhiko Imamura Shuji Joho Ryuichi Ushijima Makiko Nakamura Koichiro Kinugawa |
| author_facet | Masaki Nakagaito Teruhiko Imamura Shuji Joho Ryuichi Ushijima Makiko Nakamura Koichiro Kinugawa |
| author_sort | Masaki Nakagaito |
| collection | DOAJ |
| description | Abstract Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of SGLT2i on renal function and outcome remains uninvestigated. Methods We prospectively included 40 type 2 diabetic mellitus (T2DM) patients (median 68 years old, 29 male) who were hospitalized for decompensated HF and received SGLT2i during the index hospitalization. Of them, 24 patients had increases in estimated glomerular filtration rate (eGFR) at 12-month follow-up and 16 had decreases in eGFR. We investigated the baseline factors associating with the improvement in renal function. Results Lower plasma B-type natriuretic peptide (BNP) level and the use of renin-angiotensin system inhibitor (RASI) were independently associated with increases in eGFR during the follow-up period (p < 0.05 for both). Patients with both low plasma BNP levels and uses of RASI achieved significant increases in eGFR irrespective of the baseline HbA1c levels. Conclusions Lower plasma BNP level and the use of RASI at baseline were the key factors contributing to the renoprotective effects of SGLT2i among patients with decompensated HF and T2DM. |
| first_indexed | 2024-12-22T11:31:36Z |
| format | Article |
| id | doaj.art-a632534d158f4a3380862f9775d0dc9c |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-12-22T11:31:36Z |
| publishDate | 2021-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-a632534d158f4a3380862f9775d0dc9c2022-12-21T18:27:36ZengBMCBMC Cardiovascular Disorders1471-22612021-07-012111810.1186/s12872-021-02163-7Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failureMasaki Nakagaito0Teruhiko Imamura1Shuji Joho2Ryuichi Ushijima3Makiko Nakamura4Koichiro Kinugawa5Department of Cardiology, Toyama Rosai HosipitalSecond Department of Internal Medicine, University of ToyamaSecond Department of Internal Medicine, University of ToyamaSecond Department of Internal Medicine, University of ToyamaSecond Department of Internal Medicine, University of ToyamaSecond Department of Internal Medicine, University of ToyamaAbstract Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of the composite renal endpoint and weakens the progressive decline in renal function in patients with chronic heart failure (HF). However, a detailed mechanism of SGLT2i on renal function and outcome remains uninvestigated. Methods We prospectively included 40 type 2 diabetic mellitus (T2DM) patients (median 68 years old, 29 male) who were hospitalized for decompensated HF and received SGLT2i during the index hospitalization. Of them, 24 patients had increases in estimated glomerular filtration rate (eGFR) at 12-month follow-up and 16 had decreases in eGFR. We investigated the baseline factors associating with the improvement in renal function. Results Lower plasma B-type natriuretic peptide (BNP) level and the use of renin-angiotensin system inhibitor (RASI) were independently associated with increases in eGFR during the follow-up period (p < 0.05 for both). Patients with both low plasma BNP levels and uses of RASI achieved significant increases in eGFR irrespective of the baseline HbA1c levels. Conclusions Lower plasma BNP level and the use of RASI at baseline were the key factors contributing to the renoprotective effects of SGLT2i among patients with decompensated HF and T2DM.https://doi.org/10.1186/s12872-021-02163-7HemodynamicsCongestionChronic kidney disease |
| spellingShingle | Masaki Nakagaito Teruhiko Imamura Shuji Joho Ryuichi Ushijima Makiko Nakamura Koichiro Kinugawa Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure BMC Cardiovascular Disorders Hemodynamics Congestion Chronic kidney disease |
| title | Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| title_full | Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| title_fullStr | Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| title_full_unstemmed | Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| title_short | Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| title_sort | renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure |
| topic | Hemodynamics Congestion Chronic kidney disease |
| url | https://doi.org/10.1186/s12872-021-02163-7 |
| work_keys_str_mv | AT masakinakagaito renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure AT teruhikoimamura renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure AT shujijoho renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure AT ryuichiushijima renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure AT makikonakamura renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure AT koichirokinugawa renoprotectiveeffectsofsodiumglucosecotransporter2inhibitorsintype2diabetespatientswithdecompensatedheartfailure |